Prothena Corporation plc Logo

Email this page: News Release

Prothena Presents Clinical Results Demonstrating Robust, Rapid Reduction in Levels of Free Serum Alpha-Synuclein of Up to 96% After Single Dose of PRX002, Novel Protein Immunotherapy for Parkinson's Disease

For security reasons, registration is required before you can use this feature.
* Indicates required field